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Editorial Comment
Vasodilator Therapy in Chronic
Severe Aortic Regurgitation*
SHAHBUDIN H
. RAHIMTOOLA, MB,
FRCP, FACC
Los Angeles, CalTornia
Effects of vasodilator therapy . In moderate and severely
symptomatic patients with chronic severe aortic regurgita-
tion, an arteriolar dilator, hydralazine, resulted in reduction
of pulmonary angry wedge pressure al rest, increases of
stroke volume index and cardiac index and reduction of
systemic vascular resistance (1) . On exercise there was a
reduction of man arterial and pulmonary artery wedge
pressures, increase of cardiac index and reduction of sys-
temic vascular resistance (I). These beneficial effects were
the result of reduction of regurgitant volume, regurgitant
fraction and left ventricular end-diastolic and end-systolic
volumes ; there was a small increase in left ventricular
ejection fraction (2). In symptomatic and asymptomatic
patients with moderate to severe aortic regurgitation, one
sublingual dose of the calcium channel blocker nifedipine
produced a reduction of mean aortic, left ventricular end-
diastolic and mean pulmonary artery wedge pressures. in-
crease of cardiac index and reduction of systemic vascular
resistance (3). In a single symptomatic patient, who refused
valve replacement, long-term (14 months) hydralazine ther-
apy produced major reductions of left ventricular end-
diastolic volume and mass and normalization of reduced left
ventricular ejection fraction (4).
These findings raised important
questions
:
1) Were the
tong-term favorable effects observed in a single patient a clue
that all
or most patients so treated would have such major
improvements or would they be seen in only a minority of
patients? 2) What was the role of long-term vasodilator
therapy in symptomatic and asymptomatic patients with
chronic severe aortic regurgitation?
Symptomatic patients. In symptomatic patients with
chronic severe aortic regurgitation, long-term (ll months)
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maximal dose hydralazine therapy in addition to digitalis
plus diuretic therapy produced improvement in exercise
capacity that was associated with increased cardiac output
and reduced arterial pressure and systemic vascular resis-
tance (5). There were no significant changes in eehocardio-
graphic left ventricular dimension or fractional shortening,
radionuclide left ventricular ejection fraction at rest or
during exercise and left ventricular volumes and ejection
fraction calculated from contrast ventr:cuiography (5)
. How-
ever, analysis of individual patient data showed that major
benefits in exercise capacity and cardiac output were present
in only 37% of patients and that major reductions in left
ventricular volume and ejection fraction were present in
21%v, Thus,
it appears that the findings observed in the single
symptomatic patient (4) w repre of chose that
occurred in a minority of Symptomatic patients . Further-
more, these beneficial
effects could not be predicted from the
baseline clinical
. hemodynamic, exercise or left ventricular
function data . These findings, combined with the known
beneficial effects of valve replacement (5,6), suggest that
long-term hydralazine therapy is of limited value in most
patients with symptomatic severe aortic regurgitation .
Asymptomatic patients . In a randomized 6 month trial of
hydralazine in 17 asymptomatic patients with moderate to
severe aortic regurgitation . Kleaveland and coworkers (7)
found no significant change in treadmill exercise duration or
peak oxygen consumption and left ventricular dimension,
volume and hypertrophy . Systolic blood pressure was re-
duced and echocardiographic fractional shortening and
radionuclide exercise ejection fraction at rest were in-
creased
. Two of the eight patients treated with hydralazine
withdrew from the trial because of intoleri'le side effects
.
In a multicenter, randomized, double-blind, placebo-
controlled trial of hydralazine, Greenberg and coworkers (8)
reported on 80 patients treated for up to 24 months . Patients
were asymptomatic or minimally symptomatic and had mod-
erate to severe aortic regurgitation . No exercise tests to
determine exercise capacity were performed ; results were
assessed by clinical evaluation, M-mode echocardiography
and rest and exercise radionuclide ventriculography. Ten
(12.5%) of the 80 patients did not return for follow-up
studies
; 29% of the hydralazine-treated patients discontin-
ued the tu_rapy and "because of the spread of entry times,
dropouts and noncompliance" follow-up studies at 24
months were available for only 37 (46%) of the 80 random-
ized patients . There were no significant changes in blood
pressure, echocardiographic dimensions and fractional
shortening . The intention to treat analysis of data from
patients assigned to receive hydralazine showed significant
reduction of left ventricular end-diastolic volume by 24 ± 6
ml)m2 and end-systolic volume by 12 ± 3 mUm
2
and an
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increase in ejection fraction of 0.02 ± O.Ot units. Patients
assigned to placebo had a reduction in ejection fraction of
0.02 *_ 0
.01 units. Data from individual patients were not
presented and therefore it is not clear what percent of treated
patients showed
major improvement with therapy . Data in
symptomatic and asymptomatic patients were not separately
presented; therefore, it is not known if both subgroups were
equally benefited . Side effects were very common at 3
months and occurred in 76% of those randomized to hydrata-
zinc and in 44% of those assigned to placebo ; the contents of
the placebo were not given . At 12 months the frequency of
side effects was much lower . These two trials suggest a very
limited role of hydralazine vasodilator therapy in asympto-
matic patients with moderate to severe aortic regurgitation .
The present study . In the current issue of the Journal
Scognamiglio and coworkers (9) present the results of a 12
month, randomized . doublerblintl. placebacontrolled trial
of
nifedipine in 72 asymptomatic patients with severe aortic
regurgitation . Exercise capacity was not determined objec-
tively . Twenty-eight (39%) of the 72 patients underwent
cardiac catheterization and the echocardiographically deter-
mined left ventricular enddiastolic volume and ejection
fraction were very similar to those obtained from contrast
ventriculography
. There was a significant reduction in
echocardiographically determined left ventricular end-
diastolic volume index by 26
ml/nil
and in mass by 27 g!m-
and an increase in ejection fraction of 0 .12 units
. Data in
individual patients were not presented and thus it is not clear
what percent of patients showed a major improvement . The
incidence of side ef'ectt from nifedipine was 60% at
3 months but was much lower at 12 months
: only
one patient
discontinued nifedipine therapy and 70 (97%) of 72 cone
pleted the 12 month trial period . The placebo-treated pa-
tients had a reduction in ejection fraction of 0 .10 units .
These findings are of considerable interest . The results of
the studies of Scognamiglio et al . (9) and others (7 .8) suggest
a potential value of long-term treatment with an arteriolar
dilator in asymptomatic patients with chronic severe aortic
regurgitation. Nifedipine appears superior to hydralazine
because 1) the reduction of left ventricular end-diastolic
volume at 12 months was greater (the reduction at t2 months
with hydralazine was not significant) (B). 2) the increase in
ejection fraction was greater t0.12 versus 0 .02 units) : 3) there
was a significant reduction of left ventricular mass in the
nifdipine-treated group, and 4) the side effect profile was
very much more favorable with nifedipine and almost all
patients completed the trial. Furthermore
. the currently
available slow release form of nifedipine is expected to
provide a more uniform 24 h effect, a lower incidence of side
effects and a greatly improved patient compliance rate
because the drug can be administered only once daily (to) .
The placebo-treated patients in these two studies (8.9)
showed a reduction in left ventricular ejection fraction at rest
of 0 .02 units at 24 months in one study and ON . 10 units at I?
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months in the other. These findings appear to differ with the
natural history study of Borrow et al . (I]) of asymphimiatic
patients with severe aortic regurgitation and normal left
ventricular function at rest, which showed that only an
occasional patient developed left ventricular dysfunction
over a 7 year follow-up. However, there are differences
between the Borrow study (11) and these two studies
(8,9) .
The latter studies showed a reduction in ejection fraction but
may have included some patients with abnormal left ventric-
ular function (initial ejection fractions were 0.64 ± 0.08 and
0.56 '- 0.05 units). whereas in the study of Borrow et al . (tt)
all patients initially had normal left ventricular function .
Furthermore, neither of the two studies (8.9) stated whether
any patients with initially normal left ventricular function
merely had a reduction in ejection fraction or actually
developed left ventricular dysfunction . The data from the
110 Slu11(05 2139 sufcst that the addition of an isotropic
agent may be of value in selected patients .
Role of di iladis. Routine digitalis therapy in all asymptu
manic patients with severe aortic regurgitation has been
previously
recommended (12) . In a I month trial of digoxin .
nifedipine and hydralazine in patients with moderately se-
vere aortic regurgitation . Crawford et al . (13) showed an
improvement of left ventricular ejection fraction at rest from
0 .47 ± 0 .08 to 0.54 ~_ 0.08 units (p < 0.03) with digoxin, an
effect not seen with either hydralaane or nifedipine . Fur-
thermore. at peak exercise the ejection fraction was signifi-
cantly increased with digoxin and in the recovery period the
ejection fraction was increased with both digoxin and nife-
dipine but not with hydralazine .
Conclusiums. It appears that the addition of digitalis is
beneficial and the role of combined therapy with digitalis
plus an arteriolar dilator (a calcium channel blocking agent)
needs to be evaluated. The role of combined arteriolar and
venous dilators (for example . angiotensin-converting en-
zyme inhibitors) has also not been prospectively evaluated .
Clearly, additional studies are needed in asymptomatic pa-
tients with chronic severe aortic regurgitation and normal
left ventricular systolic function at rest as we move closer to
routine preventive cardiology in regurgitant valvular lesions
.
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